<DOC>
	<DOC>NCT02068222</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection</brief_title>
	<detailed_description>Once the efficacy and safety data were obtained from participants administered ABT-450/r + ABT-530 + RBV weight-based (Arm 1) in Study M14-213, the decision was made to end this study before subjects were enrolled into Arm 2.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male or female (of nonchild bearing potential) between 18 and 70 years of age with Body Mass Index â‰¥18 to &lt;38 kg/m2. Chronic HCV genotype 3 infection prior to study enrollment and has never received antiviral treatment for HCV. Subject has plasma HCV RNA level &gt; 10,000 IU/mL at Screening. Sexually active males must be sterile, have male partners only, or agree to use two effective forms of birth control for 7 months after stopping study drug. History of severe, lifethreatening or other significant sensitivity to any drug. Positive test result for Hepatitis B surface antigen (HBsAg) or antiHuman Immunodeficiency virus antibody (HIV Ab). Prior therapy for the treatment of HCV. Any current or past clinical evidence of cirrhosis. Any cause of liver disease other than chronic HCVinfection. HCV genotype coinfection with any other HCV genotype. Use of contraindicated medications within 2 weeks or 10 halflives of dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Interferon Free</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Hepatitis C Genotype 3</keyword>
</DOC>